Multiple Myeloma Staging Systems: Understanding Your Stage, R2-ISS Scores, and Prognostic Reality

Foreword: Key Takeaways

"Doctor, what stage is my myeloma?" "I was told I have Stage III—does that mean my cancer has spread everywhere and is terminal?" "Why does my report mention ISS, R-ISS, and Durie-Salmon at the same time?"

Receiving a multiple myeloma diagnosis can be overwhelming, and understanding medical staging reports is often the primary source of patient anxiety. Modern hematology provides clarity and reassurance:

1. Multiple Myeloma Staging Is Fundamentally Different from Solid Tumors: Unlike lung or breast cancer, myeloma does not use the TNM ("tumor-node-metastasis") system. Because myeloma is a blood cancer that originates in the bone marrow, it is recognized as a systemic condition from day one. "Stage III" in myeloma does NOT mean "terminal metastatic cancer."
2. Staging Has Evolved from "Tumor Mass" to "Genomic Biology": We have transitioned from the historical 1975 Durie-Salmon system to the modern R2-ISS (Second Revised International Staging System) and the IMS-IMWG 2024 High-Risk Consensus, which integrate chromosomal abnormalities (iFISH), genomic mutations (TP53), and cellular proliferation (LDH).
3. Advanced Stage Does Not Dictate Inevitable Outcome: In the modern era of anti-CD38 quadruplet regimens (Dara-VRd, Isa-KRd) and CAR T-cell therapies, patients with Stage III or high-risk features frequently achieve deep minimal residual disease (MRD) negativity, resulting in long-term disease-free remissions and normal life expectancy.

1. Why Myeloma Staging Differs from Solid Tumors

In solid tumors (such as breast, colon, or prostate cancer), staging follows the TNM system:

• T (Tumor size): How large the primary tumor has grown.
• N (Node involvement): Whether cancer cells have spread to nearby lymph nodes.
• M (Metastasis): Whether the tumor has spread to distant organs (e.g., liver, lungs, brain).

Solid Tumors vs. Multiple Myeloma Comparison:

• Solid Tumors (Anatomical Spread Paradigm):

  • Primary Localized Tumor (Stage I/II) → Regional Lymph Node Spread (Stage III) → Distant Organ Metastasis (Stage IV / Terminal).
• Multiple Myeloma (Systemic Blood Cancer Paradigm):

  • Plasma cells exist throughout the entire bone marrow from Day 1.
  • Staging evaluates 4 functional dimensions rather than geographical spread:

    1. Total Tumor Burden: Serum Beta-2 Microglobulin (β₂M) and M-protein levels.
    2. Host Nutrition & Microenvironment: Serum Albumin level.
    3. Cellular Proliferation Rate: Serum Lactate Dehydrogenase (LDH).
    4. Genomic Aggressiveness: Interphase FISH (del(17p), t(4;14), 1q21 gain) and TP53 gene mutation.

2. The Evolution of Myeloma Staging Systems (1975 to 2026)

Over the past 50 years, staging systems have evolved to reflect advancements in laboratory diagnostics and targeted therapies:

• 1975 (Durie-Salmon DSS): Measured physical tumor mass based on skeletal X-rays and M-protein quantities.
• 2005 (ISS): Replaced subjective X-rays with two objective blood biomarkers (Beta-2M and Albumin).
• 2015 (R-ISS): Added high-risk chromosomal genetics (iFISH) and cell turnover rate (LDH).
• 2022–2026 (R2-ISS & IMS-IMWG): Refined into a 4-tier additive point model incorporating chromosome 1q21 gain/amplification and TP53 mutations.

2.1 The Durie-Salmon Staging System (DSS, 1975)

Developed by Dr. Brian G.M. Durie and Dr. Sydney Salmon, the DSS was the first validated classification system. It estimated the total physical "bulk" (number of myeloma cells) based on bone damage and laboratory values:

• Renal Subclassification:

  • Subclass A: Normal renal function (serum creatinine < 2.0 mg/dL or < 177 μmol/L).
  • Subclass B: Abnormal renal function (serum creatinine ≥ 2.0 mg/dL or ≥ 177 μmol/L).

Modern Limitation: DSS relies on plain X-rays (which miss early bone disease) and does not capture tumor genetics. It is primarily referenced for historical context.

2.2 The International Staging System (ISS, 2005)

In 2005, the IMWG introduced the ISS, replacing subjective skeletal surveys with two objective, highly reproducible blood biomarkers: Serum β₂-Microglobulin (β₂M) and Serum Albumin.

• ISS Stage I: Serum β₂M < 3.5 mg/L AND Serum Albumin ≥ 3.5 g/dL (≥ 35 g/L).
• ISS Stage II: Neither Stage I nor Stage III (i.e., β₂M < 3.5 mg/L with albumin < 3.5 g/dL; or β₂M between 3.5 and 5.5 mg/L regardless of albumin).
• ISS Stage III: Serum β₂M ≥ 5.5 mg/L.

2.3 The Revised International Staging System (R-ISS, 2015)

To account for genomic risk and cellular proliferation in the era of novel agents, the IMWG established the R-ISS in 2015, integrating interphase FISH cytogenetics and serum Lactate Dehydrogenase (LDH):

• High-Risk Cytogenetics by iFISH: Presence of at least one of:

  • del(17p)
  • t(4;14)
  • t(14;16)
• R-ISS Staging Definitions:

  • R-ISS Stage I: ISS Stage I AND Standard-Risk Cytogenetics (no high-risk abnormalities) AND Normal Serum LDH (≤ ULN).
  • R-ISS Stage II: All other intermediate combinations not meeting Stage I or Stage III.
  • R-ISS Stage III: ISS Stage III AND EITHER High-Risk Cytogenetics OR Elevated Serum LDH (> ULN).

2.4 The Modern 4-Tier Standard: R2-ISS (2022/2024 EMN Model)

While R-ISS was a major advance, over 60% of patients fell into the broad "R-ISS Stage II" category. In 2022, the European Myeloma Network (EMN) developed the R2-ISS (Second Revision), which is incorporated into current clinical practice guidelines.

The R2-ISS uses a weighted, additive point system that removes t(14;16) and adds 1q21 gain/amplification (1q+):

R2-ISS Point Scoring Breakdown:

• ISS Stage III: +1.5 points
• ISS Stage II: +1.0 point
• del(17p) by iFISH: +1.0 point
• t(4;14) by iFISH: +1.0 point
• Elevated Serum LDH (> ULN): +1.0 point
• 1q21 Gain/Amplification (1q+): +0.5 points

R2-ISS Risk Tiers and Survival Benchmarks:

• R2-ISS Stage I (Low Risk / 0 Points): Median PFS: 68.0 months | Median OS: Not Reached.
• R2-ISS Stage II (Low-Intermediate / 0.5 to 1.0 Point): Median PFS: 45.5 months | Median OS: 109.2 months (9.1 years).
• R2-ISS Stage III (Intermediate-High / 1.5 to 2.5 Points): Median PFS: 30.2 months | Median OS: 68.5 months (5.7 years).
• R2-ISS Stage IV (High Risk / 3.0 to 5.0 Points): Median PFS: 19.9 months | Median OS: 37.9 months (3.1 years).

2.5 IMS-IMWG 2024 Consensus on High-Risk Definition

The International Myeloma Society (IMS) and IMWG established a consensus genomic model to standardize high-risk definitions in clinical practice. A patient is defined as High-Risk if they exhibit at least one of the following:

1. del(17p) and/or TP53 Mutation:

   • del(17p) must be present with a Cancer Clonal Fraction (CCF) ≥ 20% assessed on CD138-purified plasma cells.
   • And/or the presence of a pathogenic TP53 gene mutation detected by next-generation sequencing (NGS).
2. High-Risk Translocation Co-occurrence:

   • Presence of t(4;14), t(14;16), or t(14;20) co-occurring with 1q21 gain/amplification and/or del(1p32).
3. Chromosome 1 "Double Hit":

   • Monoallelic del(1p32) co-occurring with 1q+, or biallelic del(1p32).
4. Nongenomic Host Biomarker:

   • High β₂M > 5.5 mg/dL in the presence of normal renal function (serum creatinine < 1.2 mg/dL), reflecting high intrinsic tumor proliferation rather than impaired kidney filtration.

Literature References: R2-ISS (JCO 2022); IMS-IMWG Consensus (Blood 2024 / JCO 2025); R-ISS (JCO 2015)

3. Comprehensive Master Staging Comparison Table

4. "I'm Stage III—Does That Mean Terminal?"

A common reaction upon reading "Stage III" in a pathology report is extreme distress. It is essential to understand the modern medical reality:

1. Stage in Myeloma Does Not Mean Anatomical Metastasis

In solid organ oncology, Stage IV indicates that tumor cells have escaped into vital organs (such as the brain or liver), where surgical cure is no longer possible. In multiple myeloma, Stage III simply means that active plasma cells are circulating across the bone marrow compartment in higher numbers. The disease remains confined to the hematologic and skeletal systems.

2. Modern Immunotherapy Quadruplets Overcome Advanced Stages

In the past, advanced stages were associated with shorter remissions. Today, frontline quadruplet regimens (such as Dara-VRd in the PERSEUS trial or Isa-KRd in the IsKia trial) rapidly clear malignant plasma cells regardless of baseline stage:

• In the PERSEUS phase 3 trial, transplant-eligible patients treated with Dara-VRd achieved a 4-year PFS rate of 84.3% and an ultra-deep 10⁻⁶ MRD-negativity rate of 65.1%.
• In the MAIA phase 3 trial, elderly and transplant-ineligible patients on continuous Dara-Rd achieved an unprecedented median PFS of 61.9 months (over 5.1 years) and a 5-year overall survival rate of 66.6%.

3. Cellular Therapies Provide a Long-Term Safety Net

Even for patients with ultra-high-risk genetics or advanced stage who experience early relapse, BCMA-targeted CAR T-cell therapies (Cilta-cel) provide deep, durable disease control:

• In CARTITUDE-4, cilta-cel reduced the risk of disease progression or death by 71% (HR = 0.29), delivering a 30-month OS rate of 76.4%.
• In CARTITUDE-1, 33% of heavily pretreated patients remained progression-free for ≥ 5 years without any continuous maintenance therapy.

5. Diagnostic Checklist: Essential Tests for Accurate Staging

To ensure an accurate R2-ISS and IMS-IMWG staging calculation, your diagnostic workup should include the following tests:

1. Blood & Serum Biomarkers:

• Serum β₂-Microglobulin (β₂M) and Serum Albumin (for baseline ISS calculation).
• Serum Lactate Dehydrogenase (LDH) (for cell proliferation rate).
• Serum Protein Electrophoresis (SPEP), Immunofixation (IFE), and Serum Free Light Chains (sFLC).
• Serum Creatinine & Calcium (for CRAB assessment).

2. Bone Marrow Diagnostics:

• Bone Marrow Aspirate & Biopsy (morphology and plasma cell percentage).
• CD138+ Purified iFISH Panel: del(17p), t(4;14), t(14;16), t(14;20), 1q21 gain/amplification (+1q), and del(1p32).
• Targeted NGS Panel: TP53 gene mutation profiling.

3. Advanced Whole-Body Imaging:

• Low-Dose Whole-Body CT (WBLDCT) (skeletal bone survey replacement).
• Whole-Body MRI (gold standard for early bone marrow infiltration).
• ¹⁸F-FDG PET-CT (metabolic tumor activity and extramedullary lesions).

Conclusion: Knowledge Empowers Your Journey

1. Do Not Equate Stage with Prognosis: Baseline staging is a snapshot in time used to guide initial treatment intensity; your actual response to therapy (achieving deep MRD negativity) is the true determinant of your long-term outcome.
2. Ensure Complete Genomic Testing: Confirm that your bone marrow biopsy includes CD138-purified iFISH testing for del(17p), t(4;14), and 1q21 gain to accurately determine your R2-ISS score.
3. Trust in Modern Multi-Targeted Regimens: Regardless of your initial stage, four-drug induction, stem cell transplantation, and cellular immunotherapies provide reliable pathways toward prolonged remission and an active, fulfilling life.

Multiple myeloma is an increasingly manageable chronic condition. Armed with accurate staging data and personalized treatment strategies, you and your medical team are well-equipped to navigate your care with confidence and optimism.

This clinical education guide is compiled by the China Myeloma Development Network (CMDN - ChinaMyeloma.org) based on peer-reviewed literature, international clinical practice guidelines, and IMWG consensus statements. It is intended for educational purposes only and does not constitute formal medical advice. Please consult your treating hematologist or oncology team for individual clinical decision-making.